AURA
Aura Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.29
+3.11%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$6.13
From 52W high−29.33%
Volume556793.00
Market cap$652.30M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$6.13
From 52W high
−29.33%
Volume
556793.00
Market cap
$652.30M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.6x
P/E (TTM)
—
RSI (14)
45.6
MomentumView details →
1D Return
+3.11%
YTD Return
+15.59%
SummaryUpdated Jun 1, 2026
Aura Biosciences, Inc. (NASDAQ:AURA) is a clinical-stage biotechnology company founded in 2009 and headquartered in Cambridge, Massachusetts. The company went public in October 2021 and focuses on developing innovative cancer therapies using its proprietary virus-like drug conjugate (VDC) technology platform. Aura specializes in treating rare and difficult-to-treat cancers, particularly in ocular (eye-related) and urologic oncology where significant unmet medical needs exist.
Similar companies
Latest newsMore news →
Aura Biosciences reported a net loss of $45.6 million for Q2 2026, with diluted EPS of -$0.48, and announced a 20% workforce reduction as part of an organizational realignment, expecting cash runway into the first half of 2029.70d agoAura Biosciences appointed Jeremy Bender as a Class II director effective July 7, 2026.104d ago